GlaxoSmithKline and Vir finally score $1B supply deal for COVID antibody—6 months after FDA nodnews2021-11-17T14:05:49+00:00November 17th, 2021|Fierce Pharma|
Pfizer, US in talks for ‘multibillion-dollar’ supply deal for COVID-19 pill: WaPonews2021-11-16T20:44:39+00:00November 16th, 2021|Fierce Pharma|
Moderna, amid mounting pressure to address vaccine inequality, says it’s working on new COVAX dealnews2021-11-16T16:34:40+00:00November 16th, 2021|Fierce Pharma|
Viatris launched two versions of its interchangeable insulin biosimilar. Why?news2021-11-16T15:55:13+00:00November 16th, 2021|Fierce Pharma|
Viatris launched 2 versions of its interchangeable insulin biosimilar. Why?news2021-11-16T15:55:13+00:00November 16th, 2021|Fierce Pharma|
MyLife, with COVID-19 in its sights, raises cash to advance vaccine patch delivery technews2021-11-16T14:52:10+00:00November 16th, 2021|Fierce Pharma|
Novartis sees future beyond eye drops, bagging option to buy developer of drug delivery technews2021-11-16T14:22:16+00:00November 16th, 2021|Fierce Pharma|
Pharma-backed ‘Destination Healthy Skin’ RV nears end of 2021 road tournews2021-11-16T14:16:02+00:00November 16th, 2021|Fierce Pharma|
Cell and gene therapy player CBM plots expansion, 2,000 new hires with funding from South Korean partnernews2021-11-16T13:58:19+00:00November 16th, 2021|Fierce Pharma|
AbbVie’s ‘unsupported’ price hikes on Humira drove $1.4B in extra U.S. drug spending, ICER saysnews2021-11-16T13:55:38+00:00November 16th, 2021|Fierce Pharma|
